Prospective randomized trial on Pemafibrate versus omega-3-acid ethyl in patients with untreated hypertriglyceridemia

Prospective randomized trial on Pemafibrate versus omega-3-acid ethyl in patients with untreated hypertriglyceridemia - Prospective randomized trial on Pemafibrate versus omega-3-acid ethyl in patients with untreated hypertriglyceridemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037026

Enrollment

Registered

2019-06-11

Start date

2019-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia

Interventions

Pemafibrate 0.2mg/day omega 3 fatty acid ethyl 2g/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: TG>150mg/dL

Exclusion criteria

Exclusion criteria: sCr>1.5mg/dL(treating with statin) sCr>2.5mg/dL(untreating with statin) Patients who were deemed not appropriate to participate in this study by doctor

Design outcomes

Primary

Measure	Time frame
TG	—

Secondary

Measure	Time frame
LDL,HDL,T-cho,sCr,eGFR Remnant-Like Particle,Apo A-I,B,E,fatty acid fractionation,urinary albumin,cystitis C,oxidized LDL Cartotid echo,ABI,FMD	—

Countries

Japan

Contacts

Public ContactMitsue Akiyama

Sekino Laboratory Department of Research

skn-np@sekino-hospital.com03-3986-5501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026